Early adverse events and patient-reported outcomes after salvage radiotherapy following prostatectomy according to fractionation schedule: Interim analysis of the phase III URONCOR 06–24 trial
Year: 2026
Type: article
Abstract: Background and purpose Moderate hypofractionation is increasingly used in salvage radiotherapy (SRT) after radical prostatectomy, although prospective data in the postoperative setting remain limited. We evaluated early adverse events and patient-reported outcomes (PROs) according to fractionation schedule within a prospective multicenter phase III trial. Materials and methods This prespecified interim analysis included the first 250 patients enrolled in the URONCOR 06–24 randomized trial (NCT05781217). SRT was delivered using moderate hypofractionation ( n = 175), most commonly 62.5 Gy in 25 fractions (80.5%), followed by 65.25 Gy in 29 fractions (7.5%), 60 Gy in 24 fractions (4.6%), and 52.5 Gy in 20 fractions (2.9%), corresponding to a biologically equivalent dose (EQ.D2) of approximately 65–71 Gy (α/β = 1.5), or conventional fractionation ( n = 75; 66–70 Gy in 33–35 fractions). Adverse events were assessed using CTCAE v5.0. PROs were evaluated using EPIC-26 and EORTC QLQ-C30 at baseline, 3, and 6 months. Results With a median follow-up of 12.7 months, grade ≥ 2 genitourinary (GU) adverse events occurred in 21.7% of patients treated with hypofractionation versus 17.3% with conventional fractionation ( p = 0.431). Grade ≥ 2 gastrointestinal (GI) adverse events occurred in 10.8% and 4.0%, respectively ( p = 0.079). Pelvic nodal irradiation was more frequent in the hypofractionation group (39.4% vs 13.3%, p = 0.001). On multivariable analysis, age was associated with increased risk of GU ≥2 adverse events, while pelvic nodal irradiation was associated with increased risk of GI ≥2 adverse events. No clinically meaningful differences were observed in PROs. Conclusion Early adverse events after SRT were low and comparable between fractionation schedules, and moderate hypofractionation showed a similar safety profile despite more frequent pelvic irradiation. However, given the non-randomized nature of the fractionation schedules, longer follow-up and robust adjustment for treatment-selection biases are needed before drawing definitive conclusions regarding comparative safety.
Authors: Felipe Couñago, Carmen González, Alfonso Gómez-Iturriaga, Ana Álvarez, Marina Santos, Ana Boladeras, Nagore García, Sandra Fernández, Sandra Guardado, Abrahams Ocanto, Daniela Gonsalves, Luis Glaría, Ana Castaño, Patricia Martín, Laura Montezuma, Arantxa Mera, Joel Mases, Gerard Meca, Víctor Duque-Santana, Jesús Olivera, Sara Pérez, Ivan Henriquez, Bárbara Malavé, Aurora Rodríguez, Rafael García, David Büchser, Josep Garre, Manuel Altabas, Jeannette Valero, Raquel García-Gómez, Miguel Berenguer, Ángel Calvo, Rafael Ordoñez, Patricia Willisch, Aldara Candal, Neus Aymar, Esther Mayrata, Fernando López-Campos
Institutions: GenesisCare, Universidad Europea de Madrid, Hospital General Universitario Gregorio Marañón, University of the Basque Country, Hospital de Cruces, Institut Català d'Oncologia, Hospital Universitario 12 De Octubre, Hospital Universitario La Paz, Hospital Universitario Ramón y Cajal, Hospital de Sant Pau, Hospital Clínic de Barcelona, Hospital Universitario Quirónsalud Madrid, IDCQ Hospitales y Sanidad, S.L.U., Hospital Universitario Fundación Jiménez Díaz, Institut de Recerca Biomèdica Catalunya Sud, Hospital Universitari Sant Joan de Reus, Hospital Ruber Internacional, Vall d'Hebron Hospital Universitari, Hospital Universitario HM Sanchinarro, Hospital Universitari i Politècnic La Fe, Hospital Clínico Universitario Virgen de la Victoria, Hospital Universitario Son Espases
Language: English
Subfield: Urology
Field: Medicine
Domain: Health Sciences
Keywords: salvage radiotherapy, radical prostatectomy, moderate hypofractionation, fractionation schedule, early adverse events, genitourinary toxicity, gastrointestinal toxicity, pelvic nodal irradiation, patient-reported outcomes, quality of life, prostate cancer, biologically equivalent dose, age as risk factor
Open Access status: gold
Estimated APC paid: $2,430
OpenAlex ID: W7204705394
